keyword
MENU ▼
Read by QxMD icon Read
search

Cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/29045996/sicko-development-of-a-multi-disciplinary-training-concept-for-paediatric-oncology
#1
Petra Tiroke, Birte Sänger, Urs Mücke, Lea Berndt, Henrike Wittenbecher, Lorenz Grigull
Background Treating children with cancer requires multiple different skills. For the healthcare personnel (HCP) in Germany the practice of ongoing training to improve professional skills is almost non-existent. Therefore, we developed a programme called 'SICKO' to support HCPs skills and attitudes by means of a multidisciplinary workshop. Methods Following a qualitative analysis, we then designed a modular (3 day) workshop. During day one (8 h) participants learn practical skills, the fundamentals of chemotherapy, and effective communication skills...
October 18, 2017: Klinische Pädiatrie
https://www.readbyqxmd.com/read/29045948/impact-of-gastric-cancer-surgery-in-elderly-patients
#2
Tomoyuki Wakahara, Nozomi Ueno, Tetsuo Maeda, Kiyonori Kanemitsu, Takuro Yoshikawa, Shinobu Tsuchida, Akihiro Toyokawa
OBJECTIVES: This study aimed to investigate the validity of gastric cancer surgery in elderly patients. METHODS: A total of 544 patients who underwent elective gastrectomy for gastric cancer were divided into an elderly group (age ≥75 years, n = 171) and a control group (age <75 years, n = 373). The clinicopathological data of the patients were reviewed. RESULTS: The overall morbidity rate (26.3 vs. 16.1%, p = 0.005) and the incidence rate of anastomotic leakage (6...
October 19, 2017: Oncology
https://www.readbyqxmd.com/read/29045825/cerenkov-luminescence-imaging-on-evaluation-of-early-response-to-chemotherapy-of-drug-resistant-gastric-cancer
#3
Muhan Liu, Sheng Zheng, Xiaojun Zhang, Hongbo Guo, Xiaojing Shi, Xiaoyu Kang, Yawei Qu, Zhenhua Hu, Jie Tian
Apoptosis imaging enables a timely and specific assessment of treatment response in cancer patients. In this study, we applied a probe for positron emission tomography (PET), served as an optical biomaterial emitting Cerenkov photons, to in vivo optical imaging of tumor apoptosis, in order to evaluate early response to chemotherapy of drug-resistant gastric cancer. (68)Ga-DOTA-Annexin V was prepared as the apoptosis targeting probe. Wild type human gastric adenocarcinoma cell line SGC7901/WT and drug vincristine-resistant variant SGC7901/VCR were used to establish normal and vincristine-resistant xenograft to simulate treatment decision situation...
October 15, 2017: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/29045659/bevacizumab-chemotherapy-versus-chemotherapy-alone-in-elderly-patients-with-untreated-metastatic-colorectal-cancer-a-randomized-phase-ii-trial-prodige-20-study-results
#4
T Aparicio, O Bouché, J Taieb, E Maillard, S Kirscher, P-L Etienne, R Faroux, F Akouz Khemissa, F El Hajbi, C Locher, Y Rinaldi, T Lecomte, S Lavau-Denes, M Baconnier, A Oden-Gangloff, D Genet, E Paillaud, F Retornaz, E François, L Bedenne
BACKGROUND: Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance and efficacy of bevacizumab according to specific endpoints in this population. PATIENTS AND METHODS: Patients aged 75 and over were randomly assigned to bevacizumab + chemotherapy (BEV) versus chemotherapy (CT)...
September 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045555/reproductive-potential-and-performance-of-fertility-preservation-strategies-in-brca-mutated-breast-cancer-patients
#5
M Lambertini, O Goldrat, A R Ferreira, J Dechene, H A Azim, J Desir, A Delbaere, M-D t'Kint de Roodenbeke, E de Azambuja, M Ignatiadis, I Demeestere
BackgroundPreclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical data are available. This study assessed the reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.Patients and MethodsThis was a retrospective analysis of two prospective studies investigating oocyte cryopreservation and ovarian tissue cryopreservation in newly diagnosed early breast cancer patients...
October 10, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045554/veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus-placebo-with-carboplatin-paclitaxel-in-patients-with-brca1-2-locally-recurrent-metastatic-breast-cancer-randomized-phase-ii-study
#6
H S Han, V Diéras, M Robson, M Palácová, P K Marcom, A Jager, I Bondarenko, D Citrin, M Campone, M L Telli, S M Domchek, M Friedlander, B Kaufman, J E Garber, Y Shparyk, E Chmielowska, E H Jakobsen, V Kaklamani, W Gradishar, C K Ratajczak, C Nickner, Q Qin, J Qian, S P Shepherd, S J Isakoff, S Puhalla
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer...
September 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045553/randomized-controlled-trial-of-s-1-versus-docetaxel-in-patients-with-non-small-cell-lung-cancer-previously-treated-with-platinum-based-chemotherapy-east-asia-s-1-trial-in-lung-cancer
#7
H Nokihara, S Lu, T S K Mok, K Nakagawa, N Yamamoto, Y K Shi, L Zhang, R A Soo, J C Yang, S Sugawara, M Nishio, T Takahashi, K Goto, J Chang, M Maemondo, Y Ichinose, Y Cheng, W T Lim, S Morita, T Tamura
Background: Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracil-based S-1 as second- or third-line therapy compared with standard docetaxel therapy in patients with advanced NSCLC. Patients and methods: Patients with advanced NSCLC previously treated with ≥1 platinum-based therapy were randomized 1:1 to docetaxel (60 mg/m2 in Japan, 75mg/m2 at all other study sites; day 1 in a 3-week cycle) or S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle)...
September 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045543/a-predictive-model-of-pathological-response-based-on-tumor-cellularity-and-tumor-infiltrating-lymphocytes-celtil-in-her2-positive-breast-cancer-treated-with-chemo-free-dual-her2-blockade
#8
P Nuciforo, T Pascual, J Cortés, A Llombart-Cussac, R Fasani, L Paré, M Oliveira, P Galvan, N Martínez, B Bermejo, M Vidal, S Pernas, R López, M Muñoz, I Garau, L Manso, J Alarcón, E Martínez, V Rodrik-Outmezguine, J C Brase, P Villagrasa, A Prat, E Holgado
Background: The presence of stromal tumor-infiltrating lymphocytes (TILs) is associated with increased pathological complete response (pCR) and improved outcomes in HER2-positive early breast cancer (BC) treated with anti-HER2-based chemotherapy. In the absence of chemotherapy, the association of TILs with pCR following anti-HER2 therapy-only is largely unknown. Patients and methods: The PAMELA neoadjuvant trial treated 151 women with HER2-positive BC with lapatinib and trastuzumab (and hormonal therapy if hormone receptor [HR]-positive) for 18 weeks...
October 12, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045540/phase-ii-trial-of-pembrolizumab-in-patients-with-platinum-refractory-germ-cell-tumors-a-hoosier-cancer-research-network-study-gu14-206
#9
N Adra, L H Einhorn, S K Althouse, N R Ammakkanavar, D Musapatika, C Albany, D Vaughn, N H Hanna
Background: Despite remarkable results with salvage standard-dose or high-dose chemotherapy about 15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT. Patients and Methods: Single arm phase 2 trial investigating pembrolizumab 200mg IV Q3weeks until disease progression in patients with relapsed GCT and no curable options...
October 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045523/the-evolution-of-chemotherapy-for-the-treatment-of-prostate-cancer
#10
D I Quinn, H M Sandler, L G Horvath, A Goldkorn, J A Eastham
Chemotherapy has been explored as a treatment option for metastatic prostate cancer since the early 1980s. Docetaxel, a taxane chemotherapeutic, was approved for the treatment of men with metastatic castration-resistant prostate cancer in 2004, and is now standard of care for late stage disease. Recent clinical studies demonstrated that patients with metastatic castration-sensitive disease, and possibly those with high-risk localized prostate cancer also benefit from docetaxel administration, expanding the role of chemotherapy in the prostate cancer treatment landscape...
July 16, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045516/navigating-the-highlights-of-phase-iii-trials-a-watchful-eye-on-evidence-based-radiotherapy
#11
J C Trone, S Espenel, A Rehailia-Blanchard, E Guillaume, N Vial, C Rancoule, C Rodriguez-Lafrasse, M Ben Mrad, A El Meddeb Hamrouni, E Ollier, C Chargari, E Deutsch, A Vallard, N Magné
Background: Phase III randomized controlled trials (RCTs) are the cornerstone of evidence-based oncology. However, there is no exhaustive review describing the radiotherapy RTCs characteristics. The objective of the present study was to describe features of all phase III RCTs including at least a radiation therapy. Methods and materials: Requests were performed in the Medline database (via PubMed). The latest update was performed in April 2016, using the following MESH terms: 'clinical trials: phase III as topic', 'radiotherapy', 'brachytherapy', as keywords...
July 12, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045506/clinical-and-molecular-characterization-of-patients-with-cancers-of-unknown-primary-in-the-modern-era
#12
A M Varghese, A Arora, M Capanu, N Camacho, H H Won, A Zehir, J Gao, D Chakravarty, N Schultz, D S Klimstra, M Ladanyi, D M Hyman, D B Solit, M F Berger, L B Saltz
Background: On the basis of historical data, patients with cancers of unknown primary (CUP) are generally assumed to have a dismal prognosis with overall survival of less than one year. Treatment is typically cytotoxic chemotherapy guided by histologic features and the pattern of metastatic spread. The purpose of this study was to provide a clinical and pathologic description of patients with CUP in the modern era, to define the frequency of clinically actionable molecular alterations in this population, to determine how molecular testing can alter therapeutic decisions, and to investigate novel uses of next generation sequencing in the evaluation and treatment of patients with CUP...
September 26, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045452/prospective-multicenter-french-study-evaluating-the-clinical-impact-of-the-breast-cancer-intrinsic-subtype-prosigna%C3%A2-test-in-the-management-of-early-stage-breast-cancers
#13
Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, Coraline Dubot, Paul Cottu, Cyrille Huchon, Sonia Zilberman, Helene Berseneff, Cyril Foa, Rémy Salmon, Aurélie Roulot, Florence Lerebours, Anne Salomon, Nadeem Ghali, Pascale Morel, Qianyi Li, Anne Cayre, Jean-Marc Guinebretière, John Hornberger, Frédérique Penault-Llorca, Roman Rouzier
PURPOSE: The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results...
2017: PloS One
https://www.readbyqxmd.com/read/29045286/ability-of-non-strain-diastolic-parameters-to-predict-doxorubicin-induced-cardiomyopathy-a-systematic-review-with-meta-analysis
#14
Mohamed Nagiub, J V Ian Nixon, Michael C Kontos
Doxorubicin is an important cause of chemotherapy-induced cardiomyopathy. Prior studies have found conflicting results of whether non-strain diastolic parameters can predict doxorubicin- induced cardiotoxicity. We performed a systematic review of English written publications using preferred reporting items for systematic reviews and meta-analysis guidelines (PRISMA). The following inclusion criteria were applied: cancer subjects, echo-derived non-strain diastolic profile, patients compared before and after treatment to predict systolic dysfunction...
October 17, 2017: Cardiology in Review
https://www.readbyqxmd.com/read/29045265/dose-escalation-study-of-concurrent-chemoradiotherapy-with-the-use-of-involved-field-conformal-radiotherapy-and-accelerated-hyperfractionation-in-combination-with-cisplatin-and-vinorelbine-chemotherapy-for-stage-iii-non-small-cell-lung-cancer-the-final-report
#15
Naruo Yoshimura, Takuhito Tada, Yoshiya Matsumoto, Kenji Sawa, Naoki Yoshimoto, Tomohiro Suzumura, Hidenori Tanaka, Shigeki Mitsuoka, Tatsuo Kimura, Tomohiro Tamiya, Tomonori Hirashima, Tomoya Kawaguchi, Shinzoh Kudoh, Masako Hosono, Kazuto Hirata
OBJECTIVES: A phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small cell lung cancer was conducted. MATERIALS AND METHODS: We used chemotherapy of a cisplatin doublet and 2 dose levels of radiation with accelerated hyperfractionation. The radiation dose levels were: a total dose of 60 Gy in 40 fractions at level 1, and 66 Gy in 44 fractions at level 2. Eligible patients with unresectable stage III non-small cell lung cancer received cisplatin and vinorelbine...
October 17, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29045018/patient-disease-and-treatment-factors-associated-with-overall-survival-in-esthesioneuroblastoma
#16
Ryan M Carey, Joseph Godovchik, Alan D Workman, Edward C Kuan, Arjun K Parasher, Jinbo Chen, James N Palmer, Nithin D Adappa, Jason G Newman, Jason A Brant
BACKGROUND: Esthesioneuroblastomas (ENB) are uncommon and data regarding outcomes are often limited to single-institution series. The National Cancer Database (NCDB), which contains outcomes information from treatment centers across the United States, represents an opportunity to evaluate outcomes for rare diseases such as ENB across multiple institutions. METHODS: The NCDB was queried for location codes corresponding to the nasal cavity and paranasal sinuses and the histology code for ENB...
October 17, 2017: International Forum of Allergy & Rhinology
https://www.readbyqxmd.com/read/29045014/efficacy-and-toxicity-of-pegylated-liposomal-doxorubicin-based-chemotherapy-in-early-stage-breast-cancer-a-multicenter-retrospective-case-control-study
#17
Fu Ou Yang, Nicholas C Hsu, Sin-Hua Moi, Yin-Che Lu, Chia-Ming Hsieh, King-Jen Chang, Dar-Ren Chen, Chi-Wen Tu, Hwei-Chung Wang, Ming-Feng Hou
AIM: PEGylated liposomal doxorubicin (PLD) has comparable efficacy and differing toxicity from conventional anthracyclines used to treat advanced breast cancer. This study compared disease-free survival and toxicity between PLD-based and conventional anthracycline-based regimens as adjuvant treatments for early-stage breast cancer. METHODS: We analyzed disease-free survival (DFS) rates, and adverse events in 102 women with early-stage (I-IIIa) breast cancer who received adjuvant PLD-based chemotherapy from 2002 to 2008...
October 18, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29044941/clinical-significance-of-changes-in-systemic-inflammatory-markers-and-carcinoembryonic-antigen-levels-in-predicting-metastatic-colorectal-cancer-prognosis-and-chemotherapy-response
#18
In-Ho Kim, Ji Eun Lee, Ji Hyun Yang, Joon Won Jeong, Sangmi Ro, Myung Ah Lee
AIM: Metastatic colorectal cancer (mCRC) is associated with poor prognosis, and biomarkers are required for predicting survival and chemotherapy response. This study aimed to evaluate the significance of changes in systemic inflammatory markers and carcinoembryonic antigen (CEA) levels in predicting mCRC prognosis and chemotherapy response. METHODS: In this retrospective study, 503 patients who received first-line palliative chemotherapy for mCRC between 2008 and 2014 at a tertiary hospital in Korea were evaluated...
October 18, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29044863/identification-of-somatic-genetic-alterations-in-ovarian-clear-cell-carcinoma-with-next-generation-sequencing
#19
Yusuke Shibuya, Hideki Tokunaga, Sakae Saito, Kazurou Shimokawa, Fumiki Katsuoka, Li Bin, Kaname Kojima, Masao Nagasaki, Masayuki Yamamoto, Nobuo Yaegashi, Jun Yasuda
Ovarian clear cell carcinoma (OCCC) is the most refractory subtype of ovarian cancer and more prevalent in Japanese than Caucasians (25% and 5% of all ovarian cancer, respectively). The aim of this study is to discover the genomic alterations that may cause OCCC and effective molecular targets for chemotherapy. Paired genomic DNAs of 48 OCCC tissues and corresponding non-cancerous tissues were extracted from formalin-fixed, paraffin embedded specimens collected between 2007 and 2015 at Tohoku University Hospital...
October 16, 2017: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/29044862/efficacy-and-safety-of-vinorelbine-plus-cisplatin-chemotherapy-for-patients-with-recurrent-and-or-metastatic-salivary-gland-cancer-of-the-head-and-neck
#20
Min Hee Hong, Chang Gon Kim, Yoon Woo Koh, Eun Chang Choi, Jinna Kim, Sun Och Yoon, Hye Ryun Kim, Byoung Chul Cho
BACKGROUND: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. METHODS: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m(2) ) on days 1 and 8 plus cisplatin (80 mg/m(2) ) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate...
October 16, 2017: Head & Neck
keyword
keyword
11110
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"